Phase II Study of Anti-CD19 CAR-T Therapy pCAR-19B for Children and Adolescents with RelapsedRefractory B-Cell Acute Lymphoblastic Leukemia
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2026-09-15
100
Participants Needed
16
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of pCAR-19B, an anti-CD19 CAR-T cell therapy, for children and adolescents aged 3 to 21 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia. This phase II, multi-center, single-arm, open-label study focuses on patients whose leukemia has not responded to prior treatments or has relapsed. The study aims to assess the response rate and other outcomes after treatment with the investigational therapy.
Participants will first have their lymphocytes collected through leukapheresis. After the collected cells are prepared into pCAR-19B cells, patients will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine for three consecutive days. This is followed by an intravenous infusion of the pCAR-19B cells at a targeted dose. The treatment period includes careful administration and monitoring of this cell infusion.
Throughout the study, participants will undergo assessments including bone marrow evaluations, blood tests, and monitoring for adverse effects and response to treatment. Researchers will measure outcomes such as objective response rate at three months, minimal residual disease, overall survival, duration of response, relapse-free survival, and event-free survival over two years. Safety data and pharmacokinetic and pharmacodynamic parameters will also be collected. The study is planned to complete by mid-2029.
CONDITIONS
Brief Title
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Research Team
T
Tianyou Wang, M.D
Y
Yicheng Zhang, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patient or guardian agrees and signs informed consent
Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) meeting refractory or relapse conditions
Malignant cells express CD19 confirmed by flow cytometry
Bone marrow blasts 5% or higher at screening
Eastern Cooperative Oncology Group (ECOG) score 0-1
Expected survival of at least 12 weeks
Normal major organ functions including heart, kidney, liver, and blood oxygen levels
No serious mental disorder
Eligible for apheresis or blood collection without contraindications
Childbearing-age participants agree to use effective contraception from consent to 1 year post-infusion
You will not qualify if you...
Relapse of isolated extramedullary disease
Active central nervous system leukemia grade 2 or 3 at screening
Prior CAR-T or gene-modified cell therapy
Previous anti-CD19 drug treatment
Recent chemotherapy, targeted therapy, or radiotherapy within specified timeframes before screening
Positive for certain infections including hepatitis B, hepatitis C, HIV, syphilis, cytomegalovirus with abnormal viral loads
Severe heart conditions such as advanced heart failure, recent heart attack, significant arrhythmias, or cardiomyopathy
Active or uncontrolled infection within 1 week before screening
Recent moderate to severe graft-versus-host disease
Recent cerebrovascular accident or seizure within 6 months
Active autoimmune diseases
Other malignant tumors within 5 years except certain treated cancers
Recent live attenuated vaccine within 4 weeks
Participation in other interventional trials within specified timeframes
Pregnancy, breastfeeding, or planning pregnancy within 1 year after infusion
Any condition investigator deems inappropriate for participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Leukapheresis and Cell Preparation
Duration - Variable, depending on manufacturing time
Participants undergo leukapheresis to collect lymphocytes, which are then processed to create pCAR-19B cells.
1 to 2 visits
Lymphodepleting Chemotherapy
Duration - 3 days
Participants receive cyclophosphamide and fludarabine chemotherapy for 3 consecutive days to prepare the body for CAR-T cell infusion.
3 visits
pCAR-19B Cell Infusion
Duration - 1 day
Participants receive an intravenous infusion of pCAR-19B cells at the target dose.
1 visit
Follow-up and Monitoring
Duration - Up to 2 years
Participants are monitored for treatment response, safety, and side effects through visits and assessments up to two years after infusion.
Regular visits at scheduled intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of Escalating Doses of 211-At-BC8-B10 Followed by Donor Stem Cell Transplant for High-Risk AML, ALL, MDS, or Mixed-Phenotype Acute Leukemia
Study of 211At-BC8-B10 Antibody Followed by Donor Stem Cell Transplant in Adults 18 to 75 With High-Risk or Relapsed Acute Leukemia and Myelodysplastic Syndrome
Phase I Dose Escalation Study of 225Ac-DOTA-Anti-CD38 Daratumumab Added to Fludarabine, Melphalan, and Targeted Total Marrow and Lymphoid Irradiation Before Donor Stem Cell Transplant for High-Risk Leukemia and Myelodysplastic Syndrome
Randomized Study of New Immunotherapies and Stem Cell Transplantation for Adults Aged 18-65
with Acute Lymphoblastic Leukemia
Virtual Nutrition Education to Prevent Weight Gain During Maintenance Chemotherapy in Children and Adolescents with Acute Lymphoblastic Leukemia
Open-label Multi-center Study of MK-1045 for Adults and Children With Precursor B-cell Acute Lymphoblastic Leukemia
Evaluating Next-Generation Sequencing and B-Cell Recovery Monitoring to Guide Post-CART Management in Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia
Phase 12 Study of Nanobody CD5-CAR T Cell Therapy for Relapsed or Refractory CD5 T-Cell Malignancies
Phase 1 Study of FIT-CD19-CAR-T Cell Therapy Infusion with Chemotherapy in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase 1 Dose Escalation and Expansion Study of Orca-Q Engineered Donor Graft in Blood Cancer Patients Undergoing Allogeneic Stem Cell Transplantation